Compare Heron Therapeutics Inc (HRTX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Victoria's Secret & Co — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Victoria's Secret & Co trades at $86.32 (market cap $6.95B). The key difference: Victoria's Secret & Co is far larger — about 76× Heron Therapeutics Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VSXY | |
|---|---|---|
Market Cap | $91.46M | $6.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $88.50 |
52-Week Low | $0.39 | $18.72 |
Enterprise Value | $189.36M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Victoria's Secret (VSXY) trades at $87.49, up 7.42% today, with a bullish technical signal and strong momentum. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 highlight improving fundamentals, while international growth and product innovation drive positive sentiment. The stock is near its consensus price target of $88.56, with net cash flow turning positive in 2026 projections.
Outlook remains favorable with analyst consensus at Buy (55.56% of coverage), though valuation multiples like P/E of 32.45 and net margin of 3.12% suggest premium pricing. Risks include competitive pressures and reliance on international expansion, but institutional support and earnings momentum support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
